Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

ck is a process designed to facilitate the development, and expedite the review of drugs to treat serious diseases and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier.

During the first half of 2013 the Company will be having discussions with regulatory authorities regarding future clinical development plans for ibrutinib's use in patients with DLBCL. The Company expects to be able to provide further updates in the third quarter of 2013.

Conference Call and further Corporate UpdatesThe Company will hold a conference call today at 4:30 p.m. EST. To participate in the conference call, please dial 1-877-407-0778 for domestic callers and 1-201-689-8565 for international callers. To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. The archived version of the webcast will be available for 30 days on the Investor Relations section of the company's Web site at http://www.pharmacyclics.com.

Use of Non-GAAP Financial MeasuresThis press release contains non-GAAP financial measures, including operating expenses and other expenses adjusted to exclude certain non-cash expenses. These measures are not in accordance with, or an alternative to generally accepted accounting principles, or GAAP, and may be different from non-GAAP financial measures used by other companies. The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in this press release are employee related non-cash expenses. The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding various financial and business trends relating to our financial condition and results of operations. When GAAP financial measures are viewed in conjunction w
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Cellgen Diagnostics today launched ... a corporate lab for its genetic-based medical testing ... a critical component in the move from today’s ... of personalized medicine – a more predictive, preventive, ... contributions will support Cellgen’s intent to develop the ...
(Date:8/19/2014)... Robin Williams’ passing is a sad reminder ... individual. Symptoms range from slowness of voluntary movements ... severe depression. Parkinson’s disease progressively gets worse over ... neurons of the brain. As these patients struggle ... progressively gets worse, they look for options. ...
(Date:8/19/2014)... Research and Markets ... "Spectroscopy Equipment and Accessories - Global Strategic ... This report analyzes the ... in US$ Thousands by the following Product ... NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, IR ...
(Date:8/19/2014)... November 2012, the European Union (EU) mandated use of the ... PSUR – responding to the increasing need to understand and ... in many regions, the main objectives of the PBRER are ... analysis of new or emerging information on the risks of ... the potential benefits of a drug; and , ...
Breaking Biology Technology:Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... EL SEGUNDO, Calif., July 27 NASA has exercised a ... continuing support to the Space Life Sciences Directorate at NASA,s Johnson ... The work will be done by Wyle,s Integrated Science and ... the bioastronautics contract, Wyle,s work supports the International Space Station, space ...
... , , , , ... Cardium Therapeutics (NYSE Amex: CXM ) ("Cardium") reported that ... that it had now resolved matters relating to the company,s exchange ... , In the communication from NYSE Amex, Cardium ...
... , , ... Pharmaceuticals, Inc. (NYSE-AMEX: NBY ) ( http://www.novabaypharma.com ), ... treatment or prevention of a wide range of bacterial, viral ... and Chief Executive Officer, will present at the Jesup & ...
Cached Biology Technology:NASA Extends Bioastronautics Contract With Wyle for Total Value of $976 Million 2Cardium Regains Listing Compliance with NYSE Amex 2Cardium Regains Listing Compliance with NYSE Amex 3NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference 2NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference 3
(Date:8/20/2014)... life can persist in a cold, dark world. A ... that examined waters and sediments from a shallow lake ... extreme environment supports microbial ecosystems. , The National ... has implications for life in other extreme environments, both ... are published in the current edition of the science ...
(Date:8/20/2014)... State University, the Wellcome Trust Sanger Institute and the ... Mycobacterium pinnipedii from skeletons found in Peru ... is a relative of the TB bacterium that affects ... These researchers assume that seals carried the pathogens from ... lions was unexpected" comments Sebastien Gagneux, from the Swiss ...
(Date:8/20/2014)... screening outcomes of approximately 3 million infants, a team ... the University of Massachusetts Medical School, have shown that ... successfully implemented across public health newborn screening programs. Data ... 20 issue of the Journal of the American ... of SCID in newborns is higher than previously thought ...
Breaking Biology News(10 mins):University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3
... wily coyote reigns as top dog in much of the ... its larger relative, the wolf, according to a new study ... more than 30 percent lower in areas that they share ... edition of the Journal of Animal Ecology, details the results ...
... UCSF scientists are reporting what they say is a ... cells to their embryonic state, a process that transforms ... The finding, published on-line as an immediate early publication ... the strategic breakthrough reported by Shinya Yamanaka, MD, PhD, ...
... complex behaviour of primates can be understood using artificially-intelligent ... published in a special edition of Philosophical Transactions of ... Festival of Science in York. Scientists using ... some primate groups are despotic whilst others are egalitarian ...
Cached Biology News:Who's afraid of the big, bad wolf? Coyotes 2Embryonic stem cell strategy advanced with UCSF finding 2Embryonic stem cell strategy advanced with UCSF finding 3Embryonic stem cell strategy advanced with UCSF finding 4Primate behavior explained by computer 'agents' 2
Rabbit polyclonal to QKI...
... Introducing SilverSNAP Stain for Mass Spectrometry ... proteome, mass spectrometry (MS) has emerged as ... Silver staining of 2-D gels is now ... of procedures that leads ultimately to identification ...
... ammonium sulfate are compatible with thermostable enzymes ... and AmpliThem™™ DNA polymerases. You can significantly ... one experiment by adding your own enzyme, ... supplied with the kit. This capability is ...
... Kits without ammonium sulfate are compatible with ... as Taq and AmpliThem™™ DNA polymerases. You ... systems in one experiment by adding your ... the PreMixes supplied with the kit. This ...
Biology Products: